Chapter 16: HPV vaccines in immunocompromised women and men

Joel M. Palefsky, Maura L. Gillison, Howard Strickler

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

HIV-positive as well as other immunocompromised women and men have increased risk of human papillomavirus (HPV)-associated anogenital and oral cancers. The effectiveness of a HPV vaccine to reduce the incidence of these tumors in immunocompromised individuals may depend on several factors, including the effects of immunocompromise on the response to vaccination, the extent of prior infection with the HPV types included in the vaccine, whether immunocompromised women and men have tumors that contain types of HPV not in the vaccines more often than the general population, and whether or not immunization occurs before immunocompromise is severe. Clinical studies are needed to determine HPV vaccine safety and effectiveness in different populations of immunocompromised women and men.

Original languageEnglish (US)
JournalVaccine
Volume24
Issue numberSUPPL. 3
DOIs
StatePublished - Aug 21 2006

Fingerprint

Human papillomavirus 16
Papillomavirus Vaccines
Papillomaviridae
vaccines
immunocompromised population
Vaccines
Mouth Neoplasms
Population
Immunization
Neoplasms
Vaccination
neoplasms
HIV
Safety
Incidence
clinical trials
Infection
immunization
vaccination
incidence

Keywords

  • HIV
  • HPV
  • Vaccines

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this

Chapter 16 : HPV vaccines in immunocompromised women and men. / Palefsky, Joel M.; Gillison, Maura L.; Strickler, Howard.

In: Vaccine, Vol. 24, No. SUPPL. 3, 21.08.2006.

Research output: Contribution to journalArticle

Palefsky, Joel M. ; Gillison, Maura L. ; Strickler, Howard. / Chapter 16 : HPV vaccines in immunocompromised women and men. In: Vaccine. 2006 ; Vol. 24, No. SUPPL. 3.
@article{60ffe42b65aa41efa1a3098ebdb75767,
title = "Chapter 16: HPV vaccines in immunocompromised women and men",
abstract = "HIV-positive as well as other immunocompromised women and men have increased risk of human papillomavirus (HPV)-associated anogenital and oral cancers. The effectiveness of a HPV vaccine to reduce the incidence of these tumors in immunocompromised individuals may depend on several factors, including the effects of immunocompromise on the response to vaccination, the extent of prior infection with the HPV types included in the vaccine, whether immunocompromised women and men have tumors that contain types of HPV not in the vaccines more often than the general population, and whether or not immunization occurs before immunocompromise is severe. Clinical studies are needed to determine HPV vaccine safety and effectiveness in different populations of immunocompromised women and men.",
keywords = "HIV, HPV, Vaccines",
author = "Palefsky, {Joel M.} and Gillison, {Maura L.} and Howard Strickler",
year = "2006",
month = "8",
day = "21",
doi = "10.1016/j.vaccine.2006.05.120",
language = "English (US)",
volume = "24",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "SUPPL. 3",

}

TY - JOUR

T1 - Chapter 16

T2 - HPV vaccines in immunocompromised women and men

AU - Palefsky, Joel M.

AU - Gillison, Maura L.

AU - Strickler, Howard

PY - 2006/8/21

Y1 - 2006/8/21

N2 - HIV-positive as well as other immunocompromised women and men have increased risk of human papillomavirus (HPV)-associated anogenital and oral cancers. The effectiveness of a HPV vaccine to reduce the incidence of these tumors in immunocompromised individuals may depend on several factors, including the effects of immunocompromise on the response to vaccination, the extent of prior infection with the HPV types included in the vaccine, whether immunocompromised women and men have tumors that contain types of HPV not in the vaccines more often than the general population, and whether or not immunization occurs before immunocompromise is severe. Clinical studies are needed to determine HPV vaccine safety and effectiveness in different populations of immunocompromised women and men.

AB - HIV-positive as well as other immunocompromised women and men have increased risk of human papillomavirus (HPV)-associated anogenital and oral cancers. The effectiveness of a HPV vaccine to reduce the incidence of these tumors in immunocompromised individuals may depend on several factors, including the effects of immunocompromise on the response to vaccination, the extent of prior infection with the HPV types included in the vaccine, whether immunocompromised women and men have tumors that contain types of HPV not in the vaccines more often than the general population, and whether or not immunization occurs before immunocompromise is severe. Clinical studies are needed to determine HPV vaccine safety and effectiveness in different populations of immunocompromised women and men.

KW - HIV

KW - HPV

KW - Vaccines

UR - http://www.scopus.com/inward/record.url?scp=33747891189&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33747891189&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2006.05.120

DO - 10.1016/j.vaccine.2006.05.120

M3 - Article

C2 - 16950001

AN - SCOPUS:33747891189

VL - 24

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - SUPPL. 3

ER -